DEA Rulemaking on Telehealth: What Congress Needs to Know
DEA Rulemaking on Telehealth: What Congress Needs to Know
October 17, 2023 10:30 to 11:30 a.m. at the Energy & Commerce and Science, Space & Technology Committee Hearing Room
***
On October 6, the Drug Enforcement Administration (DEA) and the Department of Health and Human Services (HHS) announced they are extending the remote prescription of controlled substances flexibilities that existed during the COVID-19 public health emergency through CY2024. This is the second extension granted by the agencies. The first extension was set to expire on November 11, 2023.
The DEA has also signaled its consideration of a separate Special Registration for telemedicine prescribing for patients without requiring an in-person examination. A public comment period resulted in over 38,000 public comments submitted to the DEA – among the highest number of public comments received on a proposed rule in DEA’s history – expressing concern over proposed regulations that would severely limit remote prescribing of medically necessary controlled substances.
These events mark a broader trend by DEA to recognize telemedicine as a fundamental aspect of healthcare innovation and access.
Join us on Tuesday, October 17, from 10:30 to 11:30 a.m. at the Energy & Commerce and Science, Space & Technology Committee Hearing Room (2325 Rayburn House Office Building) for a very timely discussion about key considerations and recommendations for creating a special registration process for remote prescribing of controlled substances and anticipated next steps.
Our panel of experts includes:
> Brian Clear, MD, Chief Medical Officer, Bicycle Health
> Jessica Rigsby, JD, Vice President, Legal and Compliance, Ophelia
> Megan Herber, Principal, Faegre Drinker Consulting
> Kyle Zebley, Senior Vice President, Public Policy, ATA; Executive Director, ATA Action
Download the event flyer here:
